Thalidomide demonstrated superior efficacy in preventing the relapse of immunoglobulin G4–related disease (IgG4-RD) during a 12-month follow-up period in a placebo-controlled trial. The ...

Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated.

Thalidomide is not a drug that that impinges on just one biological pathway. That complexity could explain its multifaceted effects—from its ability to induce vascular remodeling in the adult ...

“Today, on behalf of the people of Australia, our government and this parliament offers a full unreserved and overdue apology to all thalidomide survivors, their families, loved ones and carer ...